Sylwia Feszak

Ms. Sylwia Feszak

Pomeranian Medical University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DWDominika Wokołorczyk
Dominika Wokołorczyk
WKWojciech Kluźniak
Wojciech Kluźniak
THTomasz Huzarski
Tomasz Huzarski
JGJacek Gronwald
Jacek Gronwald
ASAgata Szymiczek
Agata Szymiczek
TCThe Polish Hereditary Prostate Cancer Consortium
The Polish Hereditary Prostate Cancer Consortium

13 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
WKWojciech Kluźniak
Wojciech Kluźniak
DWDominika Wokołorczyk
Dominika Wokołorczyk
BRBogna Rusak
Bogna Rusak
THTomasz Huzarski
Tomasz Huzarski
AKAniruddh Kashyap
Aniruddh Kashyap
CCCezary Cybulski
Cezary Cybulski
Bloom Syndrome is a rare recessive disease which includes a susceptibility to various cancers. It is caused by homozygous mutations of the BLM gene. To investigate whether heterozygous carriers of a BLM mutation are predisposed to breast cancer, we sequenced BLM in 617 patients from Polish families with a strong family history of breast cancer. We detected a founder mutation (c.1642C>T, p.Gln548Ter) in 3 of the 617 breast cancer patients (0.49%) who were sequenced. Then, we genotyped 14,804 unselected breast cancer cases and 4698 cancer-free women for the founder mutation. It was identified in 82 of 14,804 (0.55%) unselected cases and in 26 of 4698 (0.55%) controls (OR = 1.0; 95%CI 0.6–1.6). Clinical characteristics of breast cancers in the BLM mutation carriers and non-carriers were similar. Loss of the wild-type BLM allele was not detected in cancers from the BLM mutation carriers. No cancer type was more common in the relatives of mutation carriers compared to relatives of non-carriers. The BLM founder mutation p.Gln548Ter, which in a homozygous state is a cause of Bloom syndrome, does not appear to predispose to breast cancer in a heterozygous state. The finding casts doubt on the designation of BLM as an autosomal dominant breast cancer susceptibility gene.

14 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Igor Jarosław FeszakIgor Jarosław Feszak
Igor Jarosław Feszak
PBPiotr Brzeziński
Piotr Brzeziński
SFSylwia Feszak
Sylwia Feszak
AKAleksandra Kitowska
Aleksandra Kitowska
MWMonika Waśkow
Monika Waśkow
TBTomasz Bączek
Tomasz Bączek
Objectives: Oral isotretinoin remains the most effective therapy for severe acne, but its exceptional efficacy is often accompanied by relatively frequent adverse effects. In this study, we quantified the frequency- and dose-related predictors of clinical and biochemical adverse effects during isotretinoin treatment in routine Polish practice. Methods: The records of 370 patients (mean age: 28 ± 12 years) who began isotretinoin treatment between June 2020 and June 2025 were reviewed. The mean daily isotretinoin and cumulative isotretinoin doses were 23.4 ± 9.1 mg and 88.3 ± 31.5 mg/kg, respectively. The adverse events documented at two-monthly visits were correlated with age and dosing. Lipid, hepatic, thyroid and prolactin panels were compared with age- and sex-matched controls using χ2 statistics and odds ratios (ORs). Results: Xerosis (70%), retinoid dermatitis (20%) and cheilitis (15.5%) predominated. Hand eczema rose with higher daily isotretinoin doses (ρ = 0.082; p = 0.037), whereas pruritus declined with greater cumulative isotretinoin exposure (ρ = −0.088; p = 0.037). Retinoid dermatitis was linked to a younger age (ρ = −0.080; p = 0.0286), whereas desquamation increased slightly with age (ρ = +0.083 p = 0.0228). Overall, dyslipidemia was twice as common as in the controls (OR: 2.06; 95% CI: 1.49–2.86; p-value: <0.0001), which was driven by an elevated total cholesterol (OR: 1.93; 95% CI: 1.34–2.77; p-value: 0.0004), LDL (OR: 3.40; 95% CI: 2.26–5.10; p-value: <0.0001) and triglycerides (OR: 1.95; 95% CI: 1.20–3.17; p-value: 0.0062) and decreased HDL (OR: 2.68; 95% CI: 1.75–4.10; p-value: <0.0001). Interestingly, hyperprolactinemia occurred eight-fold more often (OR: 8.42; 95%; 95% CI: 2.97–23.84; p-value: <0.00001). Aminotransferase and TSH elevations were infrequent and statistically non-significant. Conclusions: At moderate cumulative doses, isotretinoin was generally well tolerated; however, clinically relevant lipid and prolactin disturbances were frequent. Routine lipid and endocrine monitoring, early emollient prophylaxis and dose individualization are recommended to ensure safe isotretinoin usage in everyday practice.

11 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SFSylwia Feszak
Sylwia Feszak
Igor Jarosław FeszakIgor Jarosław Feszak
Igor Jarosław Feszak
WKWojciech Kluźniak
Wojciech Kluźniak
DWDominika Wokołorczyk
Dominika Wokołorczyk
KMKlaudia Mróz
Klaudia Mróz
CCCezary Cybulski
Cezary Cybulski
Background/Objectives: Ductal carcinoma in situ (DCIS) is the most common non-invasive form of breast cancer. It is not clear to what extent DCIS is a part of the hereditary breast/ovarian cancer syndrome caused by BRCA1/2 mutations. Therefore, we investigated the association of BRCA1/2 mutations in patients with DCIS and assessed their impact on survival. Methods: We studied 564 Polish women with DCIS for six alleles in BRCA1 (c.181T>G, c.5266dupC, c.4035delA, c.3700_3704del5, c.68_69del and c.5251C>T) and four in BRCA2 (c.658_659del, c.3847_3848del, c.5946del and c.7913_7917del). To investigate the association of BRCA1/2 founder mutations with DCIS risk, we tested 4702 controls as a reference. To analyze survival, mutation carriers were followed for an average of 110 months. Results: A BRCA1 mutation was present in seven (1.24%) cases and in twenty-two (0.47%) controls (OR = 3.27, 95%CI 1.36 to 7.87, p = 0.01). A BRCA2 mutation was present in eight (1.42%) cases versus six (0.13%) controls (OR = 11.3, 95%CI 3.9 to 32.6, p < 0.0001). Three of the fifteen cases with BRCA1/2 mutations developed invasive ipsilateral or contralateral breast cancer, on average 6 years from the diagnosis of DCIS. There were no deaths reported among the 15 mutation carriers with DCIS. Conclusions: DCIS is a part of the hereditary breast/ovarian cancer syndrome caused by BRCA1/2 mutations. Women with DCIS should receive genetic counseling and testing for BRCA1/2 mutations. BRCA1/2 mutations may predispose women to a better DCIS prognosis, but further studies are needed.

6 August 2025 in Hereditary Cancer in Clinical Practice
Verified
Journal Article
Open access
PDF file
SFSylwia Feszak
Sylwia Feszak
WKWojciech Kluźniak
Wojciech Kluźniak
IFIgor Feszak
Igor Feszak
MCMagdalena Chady
Magdalena Chady
DWDominika Wokołorczyk
Dominika Wokołorczyk
CCCezary Cybulski
Cezary Cybulski
Background: The genetic background of ductal carcinoma in situ (DCIS) has not been well explored. Previously, we reported that Polish founder mutations of BRCA1/2 confer susceptibility to DCIS. The aim of our study was to investigate the role of CHEK2 , PALB2 , NBN and RECQL mutations in the ethology of DCIS. Methods: We studied 564 Polish women with DCIS for eight Polish founder alleles, including four in CHEK2 (c.1100delC, c.444 + 1G > A, del5395 and c.470T > C), two in PALB2 (c.509_510delGA and c.172_175delTTGT), one in NBN (c.657_661delACAAA) and one in RECQL (c.1667_1667 + 3delAGTA). To investigate the association of these alleles with DCIS risk, we used mutation frequencies in cancer-free controls as a reference (4000 to 4702 controls for different variants). To analyze survival, patients were followed on average for 156 months. Results: A CHEK2 mutation (all variants combined) was associated with an increased risk of DCIS (OR = 1.7, p = 0.003). The risk was higher for CHEK2 truncating mutations (OR = 3.0, p = 0.001) than for a missense variant c.470T > C (OR = 1.5, p = 0.04). The risk was highest for carriers of CHEK2 truncating mutations with a family history of breast cancer (OR = 4.2, p = 0.01). There were no deaths reported in 52 CHEK2 mutation carriers during the follow up time. PALB2 , NBN and RECQL mutations were rare among cases and were not associated with DCIS risk in Polish women. Conclusions: Based on the current study, women with a CHEK2 mutation face an increased risk of DCIS. The presence of DCIS should be considered during surveillance of CHEK2 mutation carriers. On the other hand, DCIS patients should receive genetic counseling and testing for CHEK2 mutations.

8 August 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
PBPiotr Brzeziński
Piotr Brzeziński
Igor Jarosław FeszakIgor Jarosław Feszak
Igor Jarosław Feszak
BOBeatriz Di Martino Ortiz
Beatriz Di Martino Ortiz
SFSylwia Feszak
Sylwia Feszak
Piotr KawczakPiotr Kawczak
Piotr Kawczak
TBTomasz Baczek
Tomasz Baczek
Vulvar intraepithelial neoplasia, also known as VIN, is a non-invasive squamous lesion and precursor of squamous cell carcinoma (SCC) of the vulva. There is no screening test for vulvar intraepithelial neoplasia. Diagnosis of VIN is made clinically and confirmed with a biopsy. We describe a 66-year-old woman with a condyloma-like tumour located in the skin on the vestibule of the vagina. A biopsy sample was taken from the nodule. The definitive diagnosis is supported by the histological examination (VIN III) and immunohistochemical examination of p16(+), p53(+), and a few cell nuclei. The case provides information on the importance of multidisciplinary cooperation. Lifelong surveillance is essential since the resection of individual lesions does not guarantee the prevention of invasive cancer.